Drug resistance represents a major obstacle in cancer management, and the mechanisms
underlying stress adaptation of cancer cells in response to therapy-induced hostile …

Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

Reprogramming of cellular energy metabolism is widely accepted to be a cancer hallmark.
The deviant energetic metabolism of cancer cells-known as the Warburg effect-consists in …

Sorafenib is a multikinase inhibitor that is effective in treating advanced liver cancer.
Although its mechanism of action through several established cancer‐related protein kinase …

The multikinase inhibitor sorafenib, and opening of voltage dependent anion channels
(VDAC) by the erastin-like compound X1 promotes oxidative stress and mitochondrial …

Rationale: Increased lipid droplet (LD) formation has been linked to tumor metastasis,
stemness, and chemoresistance in various types of cancer. Here, we revealed that LD …

Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in
treating advanced renal-cell carcinoma and liver cancer. Despite its well-characterized …

Deconvolution of targets and action mechanisms of anticancer compounds is fundamental in
drug development. Here, we report on ProTargetMiner as a publicly available expandable …

Background Electron transport chain is a series of protein complexes embedded in the
process of cellular respiration, which is an important process to transfer electrons and other …

The FDA has approved 31 small-molecule kinase inhibitors (KIs) for human use as of
November 2016, with six having black box warnings for hepatotoxicity (BBW-H) in product …